KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Shares Outstanding (Diluted Average): 2010-2024

Historic Shares Outstanding (Diluted Average) for Jazz Pharmaceuticals (JAZZ) over the last 15 years, with Dec 2024 value amounting to $66.0 million.

  • Jazz Pharmaceuticals' Shares Outstanding (Diluted Average) fell 8.75% to $61.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.6 million, marking a year-over-year decrease of 8.75%. This contributed to the annual value of $66.0 million for FY2024, which is 8.41% down from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Shares Outstanding (Diluted Average) of $66.0 million as of FY2024, which was down 8.41% from $72.1 million recorded in FY2023.
  • In the past 5 years, Jazz Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $72.1 million in FY2023 and a low of $56.5 million during FY2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $66.9 million, with a median of $66.0 million in 2024.
  • In the last 5 years, Jazz Pharmaceuticals' Shares Outstanding (Diluted Average) climbed by 15.23% in 2023 and then declined by 8.41% in 2024.
  • Over the past 5 years, Jazz Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $56.5 million in 2020, then rose by 5.62% to $59.7 million in 2021, then climbed by 4.77% to $62.5 million in 2022, then rose by 15.23% to $72.1 million in 2023, then dropped by 8.41% to $66.0 million in 2024.